EXELIXIS, INC. (EXEL)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$226.2M
Cash & Equivalents
$251.8M
Quarterly Burn Rate
$14,202M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
CABOZANTINIB S-MALATE
COMETRIQ |
APPROVED | Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL), Adipocytic Sarcoma, Advanced Adult Hepatocellular Carcinoma, Advanced Cancer, Various, NOS, Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors, Advanced Hepatocellular Carcinoma, Advanced Leiomyosarcoma, Advanced Liposarcoma, Advanced Metastatic Melanoma, Advanced NSCLC, Advanced Renal Cell Carcinoma, Advanced Solid Cancers, Advanced Solid Tumor, Advanced Urothelial Carcinoma, Advanced/Metastatic, Aggressive Variant Prostate Carcinoma, Anaplastic Thyroid Cancer, Astrocytic Tumors, Basal Cell Carcinoma (BCC), Basal Cell Nevoid Syndrome (BCNS), BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Bile Duct Cancer, Bladder Cancer, Bone Metastases of a Malignant Tumor, Bone Sarcomas, Bone, Metastatic Cancer, BRAF Mutation-Related Tumors, Brain Metastases, Brain Tumor - Metastatic, Breast Cancer, Cancer, Carcinoid Tumor, Carcinoid Tumor of GI System, Carcinoma, Non-small Cell Lung Cancer, Carcinoma, Non-S |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-03 | Pdufa | — |
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT03899155 | Pan Tumor Rollover Study | PHASE2 | Recruiting | 1,500 |
| NCT04963283 | Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer | PHASE2 | Active Not Recruiting | 48 |
| NCT04289779 | Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer | PHASE2 | Active Not Recruiting | 46 |
| NCT02721459 | XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma | PHASE1 | Active Not Recruiting | 26 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.